Spotlight on Urology

Ulka Vaishampayan, MD
Credits: 1.0 CNE
Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC
Ulka Vaishampayan, MD
SUNA

Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Start

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer


Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer


Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Urology Presentations

Ulka Vaishampayan, MD
1.0 CNE
SUNA
Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Start

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer


Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer


Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Culley C. Carson,  MD, FACS, FRCS(hon)
1.0 CME / MOC
Vindico Medical Education
Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com